Principles of essentiality
Principles of voluntariness, informed consent and community agreement
Principles of non-exploitation
Principles of privacy and confidentiality
Principles of precaution and risk minimisation
Principles of professional competence
Principles of accountability and transparency
EBM is the practice of integrating individual clinical expertise with the best available clinical evidence from systematic research to maximize the quality and quantity of life for individual patients.
Institutional ethics committee(IEC): A brief insight, by Rxvichu!!RxVichuZ
This is my 26th powerpoint.....its on INSTITUTIONAL ETHICS COMMITTEE(IEC) ...also known as RESEARCH and ETHICAL COMMITTEE(REC). It focusses on the general principles, that ought to be made, while selecting subjects for study.
Brief points, under specific headings, have been included.
Do go through this, and let me know your feedbacks.
Thank you!
Vishnu.
Journal Club presentation in Nursing ResearchDhara Vyas
Journal presentation in Nursing Research,
Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic
Covid-19
Abstract
Introduction
Methodology
samples
Analysis
The Clinical and Translational Science Awards (CTSA) Program: What can it do ...CTSciNet .org
Meeting: Physician-Scientist Career Development Meeting, New York Academy of Sciences, November 3-5, 2010
Panel: Successful Strategies for the Physician-Scientist
Presentation: The Clinical and Translational Science Awards (CTSA) Program: What can it do for you?
Speaker: Lisa Guay-Woodford, M.D., Professor and Vice Chair of Genetics, CTSA director, University of Alabama, Birmingham
View online with audio at http://community.sciencecareers.org/ctscinet/groups/sessions/2010/12/the-ctsa-program.php
Principles of essentiality
Principles of voluntariness, informed consent and community agreement
Principles of non-exploitation
Principles of privacy and confidentiality
Principles of precaution and risk minimisation
Principles of professional competence
Principles of accountability and transparency
EBM is the practice of integrating individual clinical expertise with the best available clinical evidence from systematic research to maximize the quality and quantity of life for individual patients.
Institutional ethics committee(IEC): A brief insight, by Rxvichu!!RxVichuZ
This is my 26th powerpoint.....its on INSTITUTIONAL ETHICS COMMITTEE(IEC) ...also known as RESEARCH and ETHICAL COMMITTEE(REC). It focusses on the general principles, that ought to be made, while selecting subjects for study.
Brief points, under specific headings, have been included.
Do go through this, and let me know your feedbacks.
Thank you!
Vishnu.
Journal Club presentation in Nursing ResearchDhara Vyas
Journal presentation in Nursing Research,
Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic
Covid-19
Abstract
Introduction
Methodology
samples
Analysis
The Clinical and Translational Science Awards (CTSA) Program: What can it do ...CTSciNet .org
Meeting: Physician-Scientist Career Development Meeting, New York Academy of Sciences, November 3-5, 2010
Panel: Successful Strategies for the Physician-Scientist
Presentation: The Clinical and Translational Science Awards (CTSA) Program: What can it do for you?
Speaker: Lisa Guay-Woodford, M.D., Professor and Vice Chair of Genetics, CTSA director, University of Alabama, Birmingham
View online with audio at http://community.sciencecareers.org/ctscinet/groups/sessions/2010/12/the-ctsa-program.php
Integrating Disruptive Technologies Into Translational Research Hinxton Hal...Mike Romanos
Introduction to a session with the same title. Addresses the challenges in drug discovery and how disruptive technologies can help. Focusses on use of RNAi and stem cells in translational studies
We often hear about hackers and hacking in the media in a pejorative way. It's time to reclaim the word! The Urban Dictionary defines hacking as:
"To program a computer in a clever, virtuosic, and wizardly manner. Ordinary computer jockeys merely write programs; hacking is the domain of digital poets. Hacking is a subtle and arguably mystical art, equal parts wit and technical ability, that is rarely appreciated by non-hackers."
What are we talking about here? Hackers built the Internet and the World-Wide Web. Hackers wrote the Linux kernel, which now powers over 900m Android devices worldwide. In this talk for Software Aliiance Wales I look at what it means to be a hacker, and how to develop your hacking skills.
A guide to poverty in the UK, focusing on 5 key areas:
Who is in poverty
What is poverty
Levels of poverty
Causes of poverty
Consequences of poverty on society
The Asian Fund for Cancer Research, Ltd. (AFCR) is a non-profit organization committed to curing cancers that have significant impacts on Asian populations. Headquartered in Hong Kong, AFCR is uniquely positioned to implement in Asia the newest cancer research discoveries and technologies from around the world, investigate the distinct causes of cancer in Asian populations through innovative genetic and molecular research, and develop more effective therapies tailored to Asian cancer patients. AFCR is dedicated to bridging the scientific and educational gaps in cancer research and cancer prevention between Asian countries and the rest of the world through promoting, coordinating and funding international collaboration in cancer research and public education. We are fully devoted to reducing the incidence and increasing the survival rate of cancers in Asia. We encourage you to visit our website for more information about cancer prevention tips and our programs. http://afcr.org.hk/en
NIH/Career Development Award Workshop
Leslie Raffel, MD
Associate Director and Cedars-Sinai Site Director
UCLA Clinical and Translational Science Institute
Welcome Remarks and Overview of CTSI ResourcesUCLA CTSI
Welcome Remarks and Overview of CTSI Resources
Steven Dubinett, MD
Director, UCLA Clinical and Translational Science Institute
President/CEO, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center
Case reports and studies may be defined as the non-experimental description of an individual or a few of cases in terms of new or unusual presentation of the diseases, an unexpected disease course or pathophysiology, and new effects (either beneficial or detrimental) of existing medications or procedures. Although they suffer from the non-experimental nature and other potential bias and errors, case reports and studies have played and will continue to play an important part in the advancement of medicine. They often serve as "primers" leading to discoveries of new diseases/disease pathophysiology as well as development of new preventive and therapeutic measures. Case reports and case studies are also employed as a platform for the training of medical students and/or resident doctors in scientific writing and critical thinking. Although the significance of case reports and studies in medicine has being recognized since the early stage of development of clinical medicine, their value needs to be appreciated in the context of modern clinical research design and the hierarchy of strength of evidence for guiding patient care. This paper discusses case reports and studies within the big picture of clinical research, research design, and evidence-based practice.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
1. 中美临床和转化医学研究高峰论坛
2010年6月16-18日,北京,中国
Sino-American Symposium on
Clinical and Translational Research
June 16-18th, 2010 in Beijing, China
建立中、
主题: 建立中、美临床和转化医学研究合作与交流的桥梁
Focus On
Building a Bridge for Connection and Communication of
Clinical and Translational Research
Co-organized by
全球医生组织(GlobalMD)
中国医学科学院
Chinese Academy of Medical Sciences
美国国立卫生研究院
The National Institutes of Health (NIH)
Clinical Center, the United States
2. Sino-American Symposium on Clinical and Translational Research In China
Co-organized by
Chinese Academy of Medical Sciences (CAMS)
GlobalMD organization (GlobalMD)
The United States National Institutes of Health (NIH) Clinical Center
Focus: Building a Bridge for Connection and Communication of Clinical Research
The Sino-American Symposium on Clinical and Translational Research (SAS-CTR) has been organized to bring together
clinicians, researchers and health care officials, from hospitals, academia and governmental agencies. It is intended for those
involved with human subjects clinical research, multi-national clinical trials and translational “bench to bedside” implementation
of research to improve health care delivery and the application of ethical regulations for quality research and health care.
Some of the most important themes relevant to the bilateral collaborations to the U.S. and China which may be discussed
in this Symposium are:
• Perspectives and New Directions in Global Health Research,
• Infectious Diseases/Emerging infectious,
• Bioethics of Drug Trials and Human Subjects Research Protections,
• Gene Therapy and Genomics—Genetic and Cell-Based Technologies to Treat Disease,
• Cardiovascular Diseases– Early Diagnosis and Prevention of Heart Diseases
• Drug Trials and Drug Development Strategies,
• How the Study of Rare Diseases Leads to a Better Understanding of More Common Medical Problems,
• Clinical and Translational Research in Oncology,
• Stem Cell Therapeutic Studies and Guides for Clinical Trials
Purpose:
To foster China—U.S. collaboration in clinical and translational research, education / training, innovation, scientific discovery,
and global health care improvement.
Target Audience:
Physicians, clinical and biomedical researchers; health care practitioners, and medical association delegates.
Outcomes:
In addition to sharing new information regarding the updated clinical and translational research development in identified
specialty areas, after attending this Symposium, the participants should be able to:
• Have a better understanding of current status of clinical and translational research from a global, institutional and
professional perspective,
• Demonstrate knowledge of resources available to support quality clinical research in his/her professional areas of interest
• Identify feasible elements for clinical research collaboration and communication between the U.S. and China,
• Discuss research methodology and approaches appropriate for different diseases entities,
• Identify relevant international rules and bioethical concerns in clinical research and drug trials.
Sino-America Clinical and Translational Research Committee
________________________________ _______________________________
Co-Chair: Dr. Liu, Depei, MD, PhD. Co-Chair: Dr. John I. Gallin, MD
President of Chinese Academy of Med. Sciences Director of the NIH Clinical Center
Program Coordinators
Dr. Zhan, Qiming, MD, PhD., Vice President of Chinese Academy of Medical Sciences (CAMS)
Dr. Tim Shi, MD, PhD., Executive Director of GlobalMD Organization (GlobalMD)
Dr. Frederick P. Ognibene, M.D. Deputy Director, Educational Affairs and Strategic Partnerships, NIH Clinical Center
Contact information: Sino-American Symposium on Clinical and Translational Research in China
GlobalMD China office: No. 65 Fuxin road, 10th Floor, Suite 1020-22, Haidian District, Beijing, Postcode: 100036, China
Office at the Chinese Academy of Med. Sci.: No. 9 Dong dian san tiao, Eastern District, Beijing, Postcode: 100730, China
The GlobalMD Head Office: 5632 Baltimore National Pike, Suite 202, Catonsville, Maryland 21028, U.S.A.
E-mail: admin@GlobalMD.org tim@GlobalMD.org Web site: www.ChinaCTS.org
3. Preliminary Agenda Sino-American Symposium on Clinical and Translational Research in China
June 16th: Setting the vision: Global, Sino-American and Institutional
8:00 – 9:00 Opening Ceremony
by Co-Chairmen, Dr. Liu, depei, President of CAMS and Dr. John I. Gallin, Director of NIH Clinical Center
Welcome Speech by Dr. Chen Zhu, the Minister of Health, China
9:00 – 10:00 Keynote Speeches:
Trends in Globalization of Clinical and Translational Research – Current Status on Drug Development in China
By Dr. Sang, Guowei, Vice President of the Chinese National Congress, the member of CAE.
Perspectives and New Directions in the NIH Global Health Research
By Dr. Francis Collins, MD, PhD, Director of the National Institutes of Health (NIH), the U.S..
10:00 – 11:00 Translational Research Opportunities: From Basic, Curiosity-Driven Research to the Discovery of Practical
Applications – Telomerase Research for Cancer and Aging
by 2009 Nobel Medicine Laureate Carol Greider, The Johns Hopkins Univ. (invited)
11:15 – 12:00 Emerging Infections—the NIH NIAID Strategy and Global Clinical Research Case Study.
By Dr. Anthony Fauci, Director of the NIAID, NIH, the member of American Society of Sciences.
From SARS to H1N1 Flu Global Pandemic — Respiratory Infectious Diseases and Prevention Strategy in China
By Dr. Zhong, nanshan, Chairman of Chinese Society of Medicine, member of CAE
12:00 – 13:00 Lunch Break & Panel Discussion:
Focus on Practical Strategy of Collaboration and Diseases Needed to be Working Together
13:00 – 16:00 Symposia: Concurrent Clinical Research Specialty
• Clinical and Translational Research on Cancer Therapeutic solutions
(Moderator Dr. Zeng, yixin, Professor and the members of CAE, Cancer Research Institute, the CAMS )
• Drug Development and Clinical Trial (first time in human subjects) Safety Issue Monitoring
(Moderator Dr. Wei, ruquan, Professor and the member of CAE, Sichuan Univ. West China Hospital)
• Clinical Research for Infectious and Transmitted Diseases
(Moderator Dr. Chen, zhinan, Professor and the member of CAE, The 4th Military Medical University)
• Stem Cell Translational Research: Highlight the Scientific, Clinical, Regulatory, Ethical and Social Issues.
(Moderator Dr. Fu, xiaobing, Professor and the member of CAE, The PLA General Hospital)
• Translational Research for Cardio-Vascular Diseases; Drug Pharmacogenetics and Imaging Trials
(Moderator Dr. Hu, Dayi, Director for Cardio-vascular diseases Research Institute, People’s Hospital)
• Clinical Research for Endocrine-Metabolism and Auto-Immune Diseases—Diabetics Research
(Moderator Dr. Guan, youfei, Deputy Dean of Basic Medical Research Institute, Peking Univ. Med. Center)
• Respiratory System and Environmental Related Health Care Issues
(Moderator Dr. Zhong, nan shan, Professor and the member of CAE, Chairman of Chinese Medical Society)
16:00 – 17:00 Round Table Meeting: Infectious Disease/Emerging Infections and Vaccine development
17:00 – 18:00 Poster Session:
18:30 – 20:00 Welcome Bouquet:
Special Lecture: Break-Through of Stem Cells Clinical Translational Research and Applications
Dr. Curt Civin, Director for the Univ. of Maryland for Stem Cell Biology and Regenerative Medicine (Invited)
June 17th: Converting the vision into reality: Plans, Opportunities and Tools
8:30– 9:30 Advantages of Sino-American Collaboration, Communication and Opportunities: the Contribution from China
By Dr Liu, Depei, Professor and President of Chinese Academy of Medical Sciences, the member of CAE
How to study the Rare Diseases Leads to a Better Understanding of More Common Medical Problems—
The NIH Clinical Research Enterprise
by Dr. John I. Gallin, M.D., Director of the NIH Clinical Center.
9:30- 10:15 Opportunity for building up the Clinical Research-Oriented Hospitals and Institutions to face the challenges of
medical and translational research development, globally– case study in China
By Dr. Dai, Kerong, M.D., Professor and the member of CAE
Epidemiology of Enteric Disease—Vaccine Trial
By Dr. Roger Glass, Director of the NIH Fogarty International Center
10:15 – 11:15 Drug development and Evaluation under the regulations of China SFDA and the U.S. FDA, respectively.
By Dr Shao, mingli, Deputy Minister of Health and Director for the Chinese SFDA,
By Dr. Margaret Hamburg, MD,PhD. Director of the U.S. FDA Office.
11:15 – 12:00 Accreditation of Clinical Research for Research Institutions for Human Subjects Protection;
Bioethical Issue Related to Multi-National Clinical Trials.
Dr. Marjorie Speers, President of AAHRPP, the U.S.
12:00 – 13:00 Lunch Break/Panel Discussion: Clinical Drug Trials and regulatory policies in the U.S. and China
4. Preliminary Agenda Sino-American Symposium on Clinical and Translational Research in China
AFTERNOON SECTION:
June 17th: Converting the vision into reality: Plans, Opportunities and Tools
13:00 – 16:00 Symposia: Concurrent Clinical Research Specialty
• Clinical translational research on Cancer Clinical Trials
(Moderator by Dr. Jing, Zhenyu, Professor and Director of Dept. of Radiology, Peking Union Hospital)
• Drug development and clinical trial safety monitoring
(Moderator by Dr. Ding, Jian, Director of Shanghai Drug Research Institute, Chinese Academy of Sciences)
• Clinical research for infectious and transmitted diseases
(Moderator by Dr. Jin, qi, Chief Scientist and Director for the National Virology Laboratory)
• Stem Cell Translational Research: highlight the scientific, clinical, regulatory, ethical and social issues.
(Moderator Dr. Cao, yiling, President of Plastic Surgery Hospital Institute, CAMS, PUMC)
• Translational Research for Brain and Cardio-vascular Diseases
(Moderator Dr. Yang, yuejin, Professor and Vice President of Beijing Fuwai Hospital, CAMS, PUMC)
• Clinical Research for Endocrine-metabolism and Auto-immune Diseases
(Moderator Dr. Wang, Hongyang, Professor and the member of CAE, the 2nd Military University)
• Respiratory system and environmental related health care issues
(Moderator TBD)
16:00 – 17:00 Round Table Meeting: New Drug Development and Clinical Trials for Cardiovascular Diseases
17:00 – 18:00 Poster session
18:30 – 20:00: Special Dinner Lecture: BioBank—In Personalized Cancer Therapy
by Dr. Anna Barker, M.D. Deputy Director of the NCI, NIH
June 18th: Making it Happen: Management and Knowledge for Quality Clinical Research
8:30 - 9:30 Opportunities for Hospitals and Research Institutes: the NIH Common Fund supporting the Clinical and
Translational Research In global clinical research development.
By Dr. Barbara Alving, Director of the NIH’s National Center for Research Resources.
Managing the Reality of Principles of Clinical Research: Methodologies and Scientific Quality Controls and
Safety Monitoring (Speaker TBD)
Challenges of Clinical Trials in International Settings
Dr. Christine Grady, RN, Ph.D., NIH Clinical Center Department of Bioethics
9:30 – 10:15 2030 Health Care: Medical Practice — Early Diagnosis and Prevention of Heart diseases
by Dr. Yang, Yuejin, Professor and Vice President of Fuwai Hospital, the CAMS, PUMC
Epidemiology as a Tool to Study Cardiac Disease
Dan Levy, M.D., Boston Univ. School of Medicine, Director for Framingham Heart Study, National Heart, Lung, & Blood Institute
10:30 – 11:15 Health Education and Communication Network for physicians to assure quality in clinical research practice
by Dr. Ke, Yang, Deputy President of Peking Univ. and Medical Center
Physician Communication and Network—benefit for clinical research and practice
Dr Harvey Fineburg, MD. Chairman of Institute of Medicine, the U.S.
11:15 – 12:00 Recognition of the Contributions of the Pioneer Contributors in the Development of
the Sino-American clinical research initiative: The Special Awards for the Nominees
(presented by Vice Minister of Health)
12:00 – 12:30 Closing Remarks: Conclusions & Future Plans
By Dr. Zhan, qimin, M,D. Ph.D. Vice President of the Chinese Academy of Medical Sciences.
13:30—16:00 Special Meeting:
The first meeting for the Society of Chinese Clinical and Translational Research:
Seeking the Collaboration and Action Plan between the U.S. counterpart and the NIH grant support.
Around Table Meetings:
Focusing groups:
The SFDA authorized Clinical Trial Centers, Bio-Industrial Park, Pharma R&D, and CROs
On Translational collaboration in the near future to boost the research and to ensure the quality of control.
5. Keynote Speakers and Distinguished Leaders from the U.S. NIH and Health Agencies
At the Sino-American Symposium in June 16-18th, Beijing, China
NIH Senior Directors: Department of Human Health Service (DHHS):
Dr. Francis Collins, M.D., Ph.D.,
Dr. Jerry Menikoff, M.D., J.D.,
Director
Director, Office for Human Research
The U.S. National Institutes of Health(NIH)
Protections, Office of Public Health and
Science, OS, DHHS
Dr. Anthony S. Fauci, M.D., The U.S. FDA:
Director for the NIAID, NIH Dr. Margaret Hamburg, M.D.,
Director and Commissioner for
the U.S. Food and Drug Administration
Dr. Roger Glass, M.D., Ph.D.,
Director for the NIH Fogarty Int’l Center Dr. Harvey Fineburg, M.D.,
President for the Institute of Medicine, USA
Dr. John I. Gallin, M.D.,
Director for the NIH Clinical Center
Dr. Robert Califf, M.D.,
Co-Chair for the Sino-America Symposium Associate Dean for the Duke University
On Clinical and Translational Research Chairman for the Clinical and Translational
Research Center, Duke University.
Dr. Anna Barker, M.D.,
Deputy Director for
The National Cancer Center , NIH Dr. Dan Levy, M.D.
Director for Framingham Heart Study,
National Heart, Lung, and Blood Institute
Dr. Barbara Alving, M.D.,
Director for the National Cancer of
Research Resources, NIH
Dr. Marjorie Speers, PhD.
President of AAHRPP,
Former Associate Director of CDC
Dr. Christine Grady, RN, Ph.D.,
Deputy and Acting Director
Dept. of Bioethics at the NIH Clinical Center
The U.S. National Institutes of Health
6. 中美临床和转化医学研究高峰论坛 2010年6月16-18日, 北京
中国医学科学院特邀专家学者(部分名单)
中国医学科学院特邀专家学者(部分名单)
刘德培教授 Dr. Liu,Depei, MD,PhD 桑国卫教授 Dr. Sang, guowei, M.D.
中国医学科学院院长 President of CAMS Chief for China National Drug
Vice President of CAE 中国医药研发总框架师 Development Strategy Plan
中国工程院院士
中美临床和转化医学 Co-Chair for Sino- 中国工程院院士 The member of CAE
American Symposium on
高峰论坛中方主席 CTR
邵明立卫生部副部长 Dr. Shao, mingli, M.D.
戴尅戎教授 Dr. Dai, Kerong,M.D. Deputy Minister of MOH, and
Shanghai No. 9 Hospital, 兼中国SFDA局长 Commissioner of China SFDA
上海第九人民医院 The member of CAE
中国工程院院士
Dr. Liu, Qian, M.D.
刘谦卫生部副部长 Deputy Minister of MOH,
Dr. Chen, zhinan, M.D. 主管科技司,科技发展规化 in charge of Med Science and
陈智南教授 technology development
The 4th Military Medical
第四军医大学 University,
中国工程院院士 The member of CAE
杨宝峰教授 Prof. Yang, baofeng, M.D.
President of Haerbing Medical
中国工程院院士 Univ. the member of CAE
钟南山教授 Dr. Zhong, Nanshan, M.D. 哈尔滨医科大学校长
广州医学院呼吸 Director for the Institute of
Respiratory Disease,
疾病研究所所长 Ghuang Zhou Med. College
中国工程院院士 the member of CAE
曾益新教授 Dr. Zeng, xingyi, M.D.
Cancer Research Center,
中山大学肿瘤防治中心 Zhongzhan University
Dr. Wang Hongyang, MD 所长,中国科学院院士 The Member of CAE
王红阳教授
The 2nd Military Medical
中国工程院院士 University,
第二军医大学附属 the member of CAE
付小兵教授 Prof. Fu, xiaobing, M.D.
东方肝胆外科研究所 PLA General Hospital,
中国工程院院士, Life Sciences Institute,
Dr. Cheng, Shujin, MD 解放军总医院 the member of CAE
程书均教授
Cancer Institute, CAMS 生命学院院长
中国工程院院士 the member of CAE
医学科学院 魏于全教授 Dr. Wei, yuquan, M.D.
肿瘤研究所 Vice Dean of Sichuan Univ.
科学院院士,华西医学院 the member of CAS
胡大一教授 Dr. Hu, Dayi, M.D. 四川大学副校长
Director of Heart
北京大学人民医院 Disease Res. Institute,
心血管疾病研究所所长 the People’s hospital 柯阳教授 Prof. Ke, Yang, M.D.
Vice President of Peking Univ.
北京大学常务副校长 Deputy Director of Med. Center
北京大学医学部副主任 Peking Univ.
金征宇教授,主任医师 Dr. Jin, zhengyu, MD
Chief of Dept. of
北京协和医院放射科 Radiology, PUMC,
CAMS Dr. Chen, shiling, PhD.
陈士林教授
Director of Drug & Plant
中国医学科学院 Institute, Academy of
Dr. Cao,yinling, M.D. 药用植物研究所所长 Sciences
曹谊林教授
President of Plastic
中国医科院附属 Surgery Hospital,
整形医院院长 CAMS
Prof. Yang, yuejin, M.D.
杨跃进教授 Vice President of Fuwai
中国医学科学院 Cardiovascular Hospital,
丁键研究员 Dr. Ding, Jian, PhD. 附属阜外医院副院长 CAMS
中国科学院 Director of Drug Res.
上海药物研究所所长 Institute, China
Academy of Sciences
程涛教授 Dr. Cheng, tao, M.D.
V.P. of Hematology
医学科学院血液学研究所 Institute & Hospital,
管又飞教授,主任 Dr. Guan, youfei, MD, PhD 血液病医院常务副所院长 CAMS
北京大学医学部 Deputy President of Basic
Med. Research Institute,
基础医学院副院长 Peking Univ. Med. Center
蒋建东教授 Dr.Jiang, Jiandong, PhD.
Drug and Bio-products
中国医学科学院 Institute, CAMS
金奇教授,主任 Dr. Jin, Qi, PhD. Chief for
the National Lab. of Virology 医药生物技术研究所所长
病毒基因工程国家重点实验室